The primary disadvantage of issuing biotech #stock to raise capital is that #founders and owners begin to lose ownership of the company as more shares are sold. As companies grow and raise more money by issuing stocks, there may come a time when owners and founders no longer have majority control and this is a challenge for innovative roadmap and technology and products they have because soon the major #stocks holder will decide who manage company and what to do, so the policies, roadmap, R&D technologies and future of company become risky that will threat stocks price in long term for stocks holders and usually #biotechnology products need update and fully monitoring of #FDA #regulator to be stable in markets that is a risk!